Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Torii and Asahi Brewery report aldose reductase inhibitors

June 7, 1996

NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor

June 7, 1996

Sanguine's PHER-02 development

June 7, 1996

Amgen initiates first leptin clinical study

June 7, 1996

NO-1886 in phase II clinical trials

June 7, 1996

Sankyo discovers ACAT inhibitor

June 7, 1996

Hoescht reports imidobisphosphonic acid derivatives

June 7, 1996

Fujisawa claims ACAT inhibitors

June 7, 1996

Completion of phase I clinical trials on human red blood cell substitute

May 31, 1996

Celtrix announces the initiation of two phase I trials of SomatoKine

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
First-in-class non-β-lactam targeting AMR gram-negative pathogens
BioWorld Science
Antimicrobial resistance (AMR) is increasingly compromising the effectiveness of essential antibiotics, resulting in higher global mortality and morbidity rates....